Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7704973 | 0.95 | RAMP1 (0.35) | P2RX3P2RX2TAS2R14SMN1; SMN2PARP1 | |
| SCHEMBL7708206 | 0.91 | PARP1 (0.42) | P2RX3P2RX2TAS2R14ALDH1A1XBP1 | |
| SCHEMBL7710997 | 0.85 | PARP1 (0.36) | ALDH1A1PARP1 | |
| SCHEMBL6611314 | 0.81 | BRD4 (0.37) | P2RX3P2RX2PARP1 | |
| SCHEMBL7704945 | 0.78 | HDAC3 (0.44) | ALDH1A1HTTSMN1; SMN2PARP1 | |
| SCHEMBL7705016 | 0.77 | RAMP1 (0.35) | P2RX3P2RX2SMN1; SMN2RAMP1CALCRL | |
| SCHEMBL6309617 | 0.76 | HDAC1 (0.43) | ALDH1A1HTTSMN1; SMN2PARP1 | |
| SCHEMBL7711321 | 0.76 | TSHR (0.35) | PARP1 | |
| SCHEMBL7710837 | 0.75 | PARP1 (0.40) | PARP1 | |
| SCHEMBL6279101 | 0.75 | TMEM97 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |